References
- Common Toxicity Criteria v2.0 [Internet]. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD April 30, 1999, Available from: http://ctep.cancer.gov/forms/CTC-3test.html (accessed 27 November 2005)
- Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037
- Druker B J, Sawyer C L, Kantarjian H, Resta D J, Reese S F, Ford J M, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042
- Paronetto F, Popper H. Lymphocyte stimulation induced by halothane in patients with hepatitis following exposure to halothane. N Engl J Med 1970; 283: 277–280
- O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
- Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002; 16: 2160–2161
- James C, Trouette H, Marit G, Cony-Makhoul P, Mahon F X. Histological feature of acute hepatitis after imatinib mesylate treatment. Leukemia 2003; 17: 978–979
- Lin N U, Sarantopoulos S, Stone J R, Galinsky I, Stone R M, Deangelo D J, Soiffer R J. Fatal hepatic necrosis following imatinib mesylate therapy. Blood 2003; 102: 3455–3456
- Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma 2004; 45: 2349–2351
- Rule S A, O'Brien S G, Crossman L C. Managing cutaneous reactions to imatinib therapy. Blood 2002; 100: 3434–3435